Kiora Pharmaceuticals Inc (KPRX)vsModerna Inc (MRNA)
KPRX
Kiora Pharmaceuticals Inc
$2.71
+1.12%
HEALTHCARE · Cap: $11.50M
MRNA
Moderna Inc
$182.56
+5.56%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
KPRX leads profitability with a 0.0% profit margin vs -141.4%. KPRX earns a higher WallStSmart Score of 39/100 (F).
KPRX
Hold39
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KPRX.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.56
$47.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 10.8x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : KPRX
The strongest argument for KPRX centers on Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : KPRX
The primary concerns for KPRX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
KPRX profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
KPRX generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
KPRX scores higher overall (39/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiora Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs, underpinned by its expertise in drug formulation and delivery. With a strong commitment to enhancing patient outcomes and a solid research framework, Kiora's strategic partnerships and clinical advancements underscore its potential within the biopharmaceutical sector, offering an attractive investment prospect for institutional investors looking to capitalize on the next generation of therapeutics.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?